The most recent Success stories from EU Research. Select a theme or country from the menus on the left to see more articles
Tick (check) box to add article to PDF "basket"
An EU-funded project developed a simple, affordable and effective vaccine strategy to prevent the incidence of both hepatitis C virus and HIV-1. This could significantly increase the life expectancy of people receiving antiretroviral therapy for HIV-1.
Published: 27 July 2018
Using innovative nanotechnologies, an EU-funded project is developing more efficient and sustainable vaccine manufacturing processes. The cost of vaccines puts a brake on wider immunisation, so these new processes will find broad application - especially in developing economies.
Published: 19 February 2018
Viral infections are a major course of disease worldwide. Licensed antiviral drugs are currently only available for a few viruses, such as HIV, influenza and hepatitis C. Through a multi-disciplinary, inter-sectoral training programme, the ANTIVIRALS project is training a new generation of experts to develop novel antiviral drugs
Published: 10 January 2017
Liver disease is one of the leading causes of death in Egypt - second only to cardiac disease - and accounts for almost 10% of overall mortality in the country. To make headway in this area of research, two Egyptian and two EU-based partners joined forces in an EU-funded project that also highlighted the importance of the business side of science.
Published: 20 November 2015
For the first time ever, two ERC grantees, Prof. Luca G. Guidotti and Dr Matteo Iannacone, have observed in vivo how specific white blood cells, so-called cytotoxic T lymphocytes, identify, target and attack liver cells that are infected with the hepatitis B virus. To witness these immune cells in action in real time, the two scientists developed advanced, dynamic imaging techniques. An estimated 240 million people are chronically infected with hepatitis B worldwide.
Published: 28 July 2015